ARCT vs. COGT, PRTC, SIGA, AUPH, YMAB, IRON, SVRA, WVE, DNTH, and MLYS
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Cogent Biosciences (COGT), PureTech Health (PRTC), SIGA Technologies (SIGA), Aurinia Pharmaceuticals (AUPH), Y-mAbs Therapeutics (YMAB), Disc Medicine (IRON), Savara (SVRA), Wave Life Sciences (WVE), Dianthus Therapeutics (DNTH), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical preparations" industry.
Cogent Biosciences (NASDAQ:COGT) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment.
In the previous week, Cogent Biosciences had 2 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 14 mentions for Cogent Biosciences and 12 mentions for Arcturus Therapeutics. Cogent Biosciences' average media sentiment score of 0.85 beat Arcturus Therapeutics' score of 0.40 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by insiders. Comparatively, 13.8% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cogent Biosciences has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500.
Cogent Biosciences has a net margin of 0.00% compared to Cogent Biosciences' net margin of -15.65%. Cogent Biosciences' return on equity of -18.22% beat Arcturus Therapeutics' return on equity.
Arcturus Therapeutics received 153 more outperform votes than Cogent Biosciences when rated by MarketBeat users. However, 70.73% of users gave Cogent Biosciences an outperform vote while only 65.34% of users gave Arcturus Therapeutics an outperform vote.
Cogent Biosciences currently has a consensus target price of $13.67, indicating a potential upside of 74.10%. Arcturus Therapeutics has a consensus target price of $61.33, indicating a potential upside of 130.49%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Cogent Biosciences.
Arcturus Therapeutics has higher revenue and earnings than Cogent Biosciences. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Arcturus Therapeutics beats Cogent Biosciences on 13 of the 17 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
